Background: Commercially available health devices are always more common and represent a unique chance to monitor patients for prolonged periods. This study aimed to test the feasibility of a smart device-based secondary prevention program in a cohort of patients with undetermined aetiology cerebrovascular disease.Methods: Patients with non-disabling ischemic stroke and transient ischemic attack in the subacute phase were provided with a smartwatch and smart-devices to monitor various vital parameters for a 4-week period (watch group). This group was compared with a standard-of-care group. This clinical trial was registered with ClinicalTrials.gov, ID: NCT04282993.Results: In total, 161 patients were recruited, 87 in the Watch group and 74 in the control group. In the watch group, more than 90% of patients recorded the ECG at least once a day. In total, 5335 ECGs were recorded during the study. The median value of blood pressure measurements was 132 over 78 mmHg. The median oxygen saturation value was 97 %. From a clinical standpoint, nine AF episodes (10,3%) in the Watch group – vs 3 (4%) in the control group - were detected.Conclusion: Our study suggests that prevention programs for cerebrovascular disease may benefit from the implementation of new technologies.